Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences

Abstract Background CHEK2 has been recognized as a breast cancer risk gene with moderate effect. Women who have previously tested negative for a BRCA1/2 gene germline pathogenic variant may benefit from additional genetic testing for the CHEK2 c.1100del pathogenic variant. The aims of this study wer...

Full description

Bibliographic Details
Main Authors: Mary E. Velthuizen, Rob B. van der Luijt, Beja J. de Vries, Marco J. Koudijs, Eveline M. A. Bleiker, Margreet G. E. M. Ausems
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Uptake testing
CHEK2 c.1100del pathogenic variant
Breast cancer risk
Recontacting
Online Access:https://doi.org/10.1186/s13053-021-00166-1

Internet

https://doi.org/10.1186/s13053-021-00166-1

Similar Items